What is Travere Therapeutics Inc's earnings per share (EPS)?

Travere Therapeutics Inc (TVTX) reported diluted earnings per share of $-0.29 for fiscal year 2025. This represents a 92.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Travere Therapeutics Inc Financials

TVTX

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Travere Therapeutics Inc (TVTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 33/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Travere Therapeutics Inc has an operating margin of -12.8%, meaning the company retains $-13 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -138.9% the prior year.

Growth

100

Travere Therapeutics Inc's revenue surged 110.5% year-over-year to $490.7M, reflecting rapid business expansion. This strong growth earns a score of 100/100.

Leverage

Travere Therapeutics Inc has elevated debt relative to equity (D/E of 4.27), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 15/100, reflecting increased financial risk.

Liquidity

Travere Therapeutics Inc's current ratio of 2.74 indicates adequate short-term liquidity, earning a score of 52/100. The company can meet its near-term obligations, though with limited headroom.

Returns

Travere Therapeutics Inc generates a -22.3% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -544.3% the prior year.

Piotroski F-Score Neutral

6/9

Travere Therapeutics Inc passes 6 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Mixed

-1.48x

For every $1 of reported earnings, Travere Therapeutics Inc generates $-1.48 in operating cash flow ($37.8M OCF vs -$25.5M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Interest Coverage At Risk

-5.8x

Travere Therapeutics Inc earns $-5.8 in operating income for every $1 of interest expense (-$62.8M vs $10.7M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$490.7M

YoY+110.5%

5Y CAGR+19.9%

10Y CAGR+17.3%

Travere Therapeutics Inc generated $490.7M in revenue in fiscal year 2025. This represents an increase of 110.5% from the prior year.

EBITDA

-$2.1M

YoY+99.3%

Travere Therapeutics Inc's EBITDA was -$2.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 99.3% from the prior year.

Net Income

-$25.5M

YoY+92.1%

Travere Therapeutics Inc reported -$25.5M in net income in fiscal year 2025. This represents an increase of 92.1% from the prior year.

EPS (Diluted)

$-0.29

YoY+92.9%

Travere Therapeutics Inc earned $-0.29 per diluted share (EPS) in fiscal year 2025. This represents an increase of 92.9% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$93.0M

YoY+58.9%

5Y CAGR+1.9%

10Y CAGR+9.4%

Travere Therapeutics Inc held $93.0M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

92M

YoY+5.5%

5Y CAGR+12.0%

10Y CAGR+9.7%

Travere Therapeutics Inc had 92M shares outstanding in fiscal year 2025. This represents an increase of 5.5% from the prior year.

Margins & Returns

Gross Margin

97.9%

YoY+1.2pp

5Y CAGR+1.0pp

10Y CAGR+0.1pp

Travere Therapeutics Inc's gross margin was 97.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 1.2 percentage points from the prior year.

Operating Margin

-12.8%

YoY+126.1pp

5Y CAGR+76.0pp

10Y CAGR+38.0pp

Travere Therapeutics Inc's operating margin was -12.8% in fiscal year 2025, reflecting core business profitability. This is up 126.1 percentage points from the prior year.

Net Margin

-5.2%

YoY+132.7pp

5Y CAGR+80.2pp

10Y CAGR-122.6pp

Travere Therapeutics Inc's net profit margin was -5.2% in fiscal year 2025, showing the share of revenue converted to profit. This is up 132.7 percentage points from the prior year.

Return on Equity

-22.3%

YoY+522.0pp

5Y CAGR+58.0pp

10Y CAGR-61.3pp

Travere Therapeutics Inc's ROE was -22.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 522.0 percentage points from the prior year.

Capital Allocation

R&D Spending

$206.0M

YoY-5.3%

5Y CAGR+9.3%

10Y CAGR+15.1%

Travere Therapeutics Inc invested $206.0M in research and development in fiscal year 2025. This represents a decrease of 5.3% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

TVTX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$490.7M+110.5%	$233.2M+60.5%	$145.2M+32.7%	$109.5M-17.0%	$131.8M-33.5%	$198.3M
Cost of Revenue	$10.3M+33.5%	$7.7M-32.4%	$11.4M+159.0%	$4.4M+15.8%	$3.8M-37.7%	$6.1M
Gross Profit	$480.4M+113.1%	$225.4M+68.5%	$133.8M+27.4%	$105.0M-17.9%	$128.0M-33.4%	$192.2M
R&D Expenses	$206.0M-5.3%	$217.5M-11.2%	$245.0M+3166.5%	$7.5M-96.3%	$201.2M+52.7%	$131.8M
SG&A Expenses	$337.2M+27.7%	$264.1M-0.5%	$265.5M+34.4%	$197.5M+56.4%	$126.3M-7.0%	$135.8M
Operating Income	-$62.8M+80.6%	-$323.8M+16.6%	-$388.1M-21.4%	-$319.8M-60.4%	-$199.4M-13.2%	-$176.2M
Interest Expense	$10.7M-3.9%	$11.2M-1.0%	$11.3M+2.7%	$11.0M-44.2%	$19.7M+3.1%	$19.1M
Income Tax	$988K+723.3%	$120K-46.2%	$223K-28.8%	$313K-23.5%	$409K+102.1%	-$19.4M
Net Income	-$25.5M+92.1%	-$321.5M-188.6%	-$111.4M+60.0%	-$278.5M-54.6%	-$180.1M-6.3%	-$169.4M
EPS (Diluted)	$-0.29+92.9%	$-4.08-172.0%	$-1.50+65.7%	$-4.37-45.2%	$-3.01+15.4%	$-3.56

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$129.7M-21.3%	$164.9M+44.0%	$114.4M+40.0%	$81.7M+9.3%	$74.8M+18.9%	$62.9M+16.2%	$54.1M+30.8%	$41.4M
Cost of Revenue	$2.6M+61.1%	$1.6M+4.2%	$1.5M-67.5%	$4.7M+83.3%	$2.6M+57.0%	$1.6M-21.1%	$2.1M+37.0%	$1.5M
Gross Profit	$127.1M-22.1%	$163.3M+44.6%	$112.9M+46.6%	$77.1M+6.7%	$72.2M+17.9%	$61.3M+17.7%	$52.1M+30.6%	$39.9M
R&D Expenses	$57.9M+11.5%	$51.9M+5.1%	$49.4M+5.3%	$46.9M-24.5%	$62.1M+20.1%	$51.7M-4.9%	$54.3M+9.9%	$49.4M
SG&A Expenses	$101.7M+17.6%	$86.5M+13.4%	$76.2M+4.6%	$72.8M+4.8%	$69.5M+5.9%	$65.6M+1.3%	$64.8M+0.9%	$64.2M
Operating Income	-$32.4M-230.1%	$24.9M+297.1%	-$12.7M+70.4%	-$42.7M+29.7%	-$60.7M-8.2%	-$56.1M+17.1%	-$67.7M+51.4%	-$139.2M
Interest Expense	$2.3M-16.6%	$2.8M-3.3%	$2.8M-0.4%	$2.9M+1.4%	$2.8M+1.4%	$2.8M-0.4%	$2.8M-0.4%	$2.8M
Income Tax	$921K+11412.5%	$8K-60.0%	$20K-48.7%	$39K+154.2%	-$72K+14.3%	-$84K-198.8%	$85K-55.5%	$191K
Net Income	$2.7M-89.4%	$25.7M+301.5%	-$12.8M+69.1%	-$41.2M+31.6%	-$60.3M-9.9%	-$54.8M+22.2%	-$70.4M+48.3%	-$136.1M
EPS (Diluted)	N/A	$0.28+300.0%	$-0.14+70.2%	$-0.47	N/A	$-0.70+23.1%	$-0.91+48.3%	$-1.76

TVTX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$605.2M+1.9%	$594.1M-24.7%	$788.9M+17.3%	$672.6M-13.4%	$776.6M+27.9%	$607.4M
Current Assets	$437.6M+5.0%	$416.7M-32.4%	$616.8M+26.8%	$486.4M-16.5%	$582.8M+42.0%	$410.4M
Cash & Equivalents	$93.0M+58.9%	$58.5M+0.6%	$58.2M-5.7%	$61.7M-62.8%	$165.8M+95.5%	$84.8M
Inventory	$36.2M-13.6%	$41.9M+344.8%	$9.4M+108.0%	$4.5M-38.2%	$7.3M-3.9%	$7.6M
Accounts Receivable	$80.1M+195.5%	$27.1M+28.0%	$21.2M+27.2%	$16.6M+4.6%	$15.9M-0.1%	$15.9M
Goodwill	N/A	$800K0.0%	$800K0.0%	$800K-11.1%	$900K0.0%	$900K
Total Liabilities	$490.4M-8.4%	$535.0M-9.0%	$588.1M-6.6%	$629.7M+32.7%	$474.5M+19.8%	$396.2M
Current Liabilities	$159.9M-20.3%	$200.8M+12.8%	$177.9M+25.1%	$142.2M+14.6%	$124.1M+33.9%	$92.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$114.8M+94.4%	$59.1M-70.6%	$200.8M+368.6%	$42.9M-85.8%	$302.1M+43.0%	$211.2M
Retained Earnings	-$1.5B-1.8%	-$1.4B-28.6%	-$1.1B-11.0%	-$1.0B-32.4%	-$766.0M-30.7%	-$585.9M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$605.2M+12.4%	$538.6M-3.0%	$555.3M+1.2%	$548.8M-7.6%	$594.1M+17.8%	$504.4M-8.5%	$551.1M-16.9%	$663.5M
Current Assets	$437.6M+17.9%	$371.1M-2.2%	$379.6M+1.4%	$374.2M-10.2%	$416.7M+28.3%	$324.7M-12.0%	$369.0M-23.3%	$481.1M
Cash & Equivalents	$93.0M-16.1%	$110.9M+47.6%	$75.2M+21.4%	$61.9M+5.7%	$58.5M+60.8%	$36.4M+12.8%	$32.3M-25.3%	$43.3M
Inventory	$36.2M-3.7%	$37.5M-0.4%	$37.7M-0.9%	$38.0M-9.2%	$41.9M-2.4%	$42.9M-0.2%	$43.0M+1.6%	$42.3M
Accounts Receivable	$80.1M-3.4%	$83.0M+114.3%	$38.7M+12.6%	$34.4M+26.8%	$27.1M+7.7%	$25.2M+2.9%	$24.5M+7.6%	$22.7M
Goodwill	N/A	$800K0.0%	$800K0.0%	$800K0.0%	$800K0.0%	$800K0.0%	$800K0.0%	$800K
Total Liabilities	$490.4M+5.5%	$465.0M-11.0%	$522.6M+1.3%	$516.0M-3.6%	$535.0M0.0%	$534.9M-0.2%	$536.0M-9.1%	$589.5M
Current Liabilities	$159.9M+18.4%	$135.1M-28.7%	$189.5M+3.9%	$182.5M-9.1%	$200.8M+5.6%	$190.0M+56.7%	$121.3M-30.0%	$173.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$114.8M+56.1%	$73.6M+124.6%	$32.7M-0.2%	$32.8M-44.4%	$59.1M+294.0%	-$30.5M-301.1%	$15.1M-79.6%	$74.1M
Retained Earnings	-$1.5B+0.2%	-$1.5B+1.7%	-$1.5B-0.9%	-$1.5B-2.8%	-$1.4B-4.3%	-$1.4B-4.1%	-$1.3B-5.6%	-$1.3B

TVTX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$37.8M+115.9%	-$237.5M+15.2%	-$280.0M-50.3%	-$186.3M-1159.4%	-$14.8M+65.4%	-$42.7M
Capital Expenditures	N/A	N/A	$668K+249.7%	$191K-96.3%	$5.1M-24.6%	$6.8M
Free Cash Flow	N/A	N/A	-$280.7M-50.5%	-$186.5M-837.4%	-$19.9M+59.8%	-$49.5M
Investing Cash Flow	$27.9M-71.9%	$99.3M+78.1%	$55.8M+271.3%	-$32.6M+76.3%	-$137.6M-124.4%	-$61.3M
Financing Cash Flow	-$33.5M-124.0%	$139.4M-36.3%	$218.8M+86.1%	$117.6M-49.3%	$231.7M+81.4%	$127.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$60.7M+323.8%	$14.3M+187.3%	$5.0M+111.8%	-$42.2M-18.1%	-$35.7M+16.0%	-$42.5M-5.6%	-$40.2M+66.2%	-$119.0M
Capital Expenditures	N/A	$140K	N/A	N/A	N/A	$0-100.0%	$82K	$0
Free Cash Flow	N/A	$14.2M	N/A	N/A	N/A	-$42.5M-5.4%	-$40.3M+66.1%	-$119.0M
Investing Cash Flow	-$104.8M-221.1%	$86.6M+1685.4%	$4.8M-88.3%	$41.3M+151.4%	-$80.3M-274.1%	$46.1M+61.2%	$28.6M-72.7%	$104.9M
Financing Cash Flow	$26.7M+140.8%	-$65.3M-4529.8%	$1.5M-60.3%	$3.7M-97.3%	$139.1M+302332.6%	$46K-94.1%	$782K+249.0%	-$525K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

TVTX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	97.9%+1.2pp	96.7%+4.6pp	92.1%-3.8pp	96.0%-1.1pp	97.1%+0.2pp	96.9%
Operating Margin	-12.8%+126.1pp	-138.9%+128.4pp	-267.2%+24.9pp	-292.2%-140.9pp	-151.3%-62.4pp	-88.8%
Net Margin	-5.2%+132.7pp	-137.9%-61.2pp	-76.7%+177.7pp	-254.4%-117.8pp	-136.6%-51.2pp	-85.4%
Return on Equity	-22.3%+522.0pp	-544.3%-488.8pp	-55.5%+594.4pp	-649.9%-590.3pp	-59.6%+20.6pp	-80.2%
Return on Assets	-4.2%+49.9pp	-54.1%-40.0pp	-14.1%+27.3pp	-41.4%-18.2pp	-23.2%+4.7pp	-27.9%
Current Ratio	2.74+0.7	2.08-1.4	3.47+0.0	3.42-1.3	4.70+0.3	4.43
Debt-to-Equity	4.27-4.8	9.06+6.1	2.93-11.8	14.70+13.1	1.57-0.3	1.88
FCF Margin	N/A	N/A	-193.3%-22.9pp	-170.4%-155.3pp	-15.1%+9.9pp	-25.0%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	98.0%-1.0pp	99.0%+0.4pp	98.7%+4.4pp	94.3%-2.3pp	96.6%-0.8pp	97.4%+1.2pp	96.2%-0.2pp	96.4%
Operating Margin	-25.0%-40.1pp	15.1%+26.2pp	-11.1%+41.2pp	-52.2%+29.0pp	-81.2%+8.1pp	-89.3%+35.8pp	-125.1%+211.4pp	-336.5%
Net Margin	2.1%-13.5pp	15.6%+26.7pp	-11.1%+39.3pp	-50.4%+30.1pp	-80.6%+6.6pp	-87.1%+43.0pp	-130.1%+198.8pp	-328.9%
Return on Equity	2.4%-32.6pp	34.9%+73.9pp	-39.0%+86.7pp	-125.6%-23.6pp	-102.0%	N/A	-464.8%-281.1pp	-183.7%
Return on Assets	0.4%-4.3pp	4.8%+7.1pp	-2.3%+5.2pp	-7.5%+2.6pp	-10.1%+0.7pp	-10.9%+1.9pp	-12.8%+7.7pp	-20.5%
Current Ratio	2.74-0.0	2.75+0.7	2.00-0.0	2.05-0.0	2.08+0.4	1.71-1.3	3.04+0.3	2.78
Debt-to-Equity	4.27-2.1	6.32-9.6	15.96+0.2	15.72+6.7	9.06+26.6	-17.56-52.9	35.38+27.4	7.96
FCF Margin	N/A	8.6%	N/A	N/A	N/A	-67.6%+6.9pp	-74.5%+213.1pp	-287.6%

Similar Companies

Amicus Therapeut FOLD

$4.5B

Agios Pharmaceuticals Inc AGIO

$1.7B

Belite Bio, Inc BLTE

$5.9B

Apogee Therapeutics Inc APGE

$5.9B

Tarsus Pharmaceuticals, Inc. TARS

$2.8B

Frequently Asked Questions

What is Travere Therapeutics Inc's annual revenue?

Travere Therapeutics Inc (TVTX) reported $490.7M in total revenue for fiscal year 2025. This represents a 110.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Travere Therapeutics Inc's revenue growing?

Travere Therapeutics Inc (TVTX) revenue grew by 110.5% year-over-year, from $233.2M to $490.7M in fiscal year 2025.

Is Travere Therapeutics Inc profitable?

No, Travere Therapeutics Inc (TVTX) reported a net income of -$25.5M in fiscal year 2025, with a net profit margin of -5.2%.

What is Travere Therapeutics Inc's EBITDA?

Travere Therapeutics Inc (TVTX) had EBITDA of -$2.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Travere Therapeutics Inc's gross margin?

Travere Therapeutics Inc (TVTX) had a gross margin of 97.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Travere Therapeutics Inc's operating margin?

Travere Therapeutics Inc (TVTX) had an operating margin of -12.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Travere Therapeutics Inc's net profit margin?

Travere Therapeutics Inc (TVTX) had a net profit margin of -5.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Travere Therapeutics Inc's return on equity (ROE)?

Travere Therapeutics Inc (TVTX) has a return on equity of -22.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Travere Therapeutics Inc's operating cash flow?

Travere Therapeutics Inc (TVTX) generated $37.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Travere Therapeutics Inc's total assets?

Travere Therapeutics Inc (TVTX) had $605.2M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Travere Therapeutics Inc spend on research and development?

Travere Therapeutics Inc (TVTX) invested $206.0M in research and development during fiscal year 2025.

How many shares does Travere Therapeutics Inc have outstanding?

Travere Therapeutics Inc (TVTX) had 92M shares outstanding as of fiscal year 2025.

What is Travere Therapeutics Inc's current ratio?

Travere Therapeutics Inc (TVTX) had a current ratio of 2.74 as of fiscal year 2025, which is generally considered healthy.

What is Travere Therapeutics Inc's debt-to-equity ratio?

Travere Therapeutics Inc (TVTX) had a debt-to-equity ratio of 4.27 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Travere Therapeutics Inc's return on assets (ROA)?

Travere Therapeutics Inc (TVTX) had a return on assets of -4.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Travere Therapeutics Inc's Piotroski F-Score?

Travere Therapeutics Inc (TVTX) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Travere Therapeutics Inc's earnings high quality?

Travere Therapeutics Inc (TVTX) has an earnings quality ratio of -1.48x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Travere Therapeutics Inc cover its interest payments?

Travere Therapeutics Inc (TVTX) has an interest coverage ratio of -5.8x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Travere Therapeutics Inc?

Travere Therapeutics Inc (TVTX) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.